Meyer N, et al. - Using the IBM MarketScan Databases, researchers evaluated the frequency and costs of revascularization procedures over a 12-month follow-up among adults (≥18 years) with stable ischemic heart disease (SIHD) who initiated ranolazine vs traditional antianginals as second or third line therapy between 2008-2016. This study included overall 108,741 patients with SIHD with treatment initiated with ranolazine, beta-blocker (BB), calcium channel blocker (CCB), or long-acting nitrate (LAN) in 18%, 21%, 24%, and 37%, respectively. Findings revealed fewer revascularization procedures and lower associated healthcare costs associated with ranolazine treatment vs initiating treatment with BB or LAN, in patients with SIHD; these benefits of ranolazine treatment were comparable to those seen in patients initiating CCBs, as were costs.